Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IdeS for Desensitization in Highly HLA-Sensitized Kidney Transplant Patients
NCT02426684Phase 2Completed
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Jun 2015
- Primary completion
- Nov 2017
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of imlifidase in antibody mediated rejection (AMR), sponsored by Cedars-Sinai Medical Center. Started Jun 2015; status: completed.
02
Drugs
imlifidase
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT02426684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02426684.